Laporan Laba Rugi (TTM)
Laporan Laba Rugi Verona Pharma plc - Depositary Receipt (Common Stock) menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40 | 40 | 40 | 40 | 0 | 0 | 0 | 0 | 0 | 6 | 42 | 119 | 222 |
| Change (%) | 0.00 | 0.00 | 0.00 | -100.00 | ∞ | 0.00 | 0.00 | 0.00 | 1,127.95 | 651.76 | 180.36 | 87.01 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |
| Cost Of Sales | 0 | 0 | 0 | 0 | 1 | 3 | 6 | 11 | |||||
| Change (%) | 0.00 | 0.00 | 0.00 | 56.94 | 375.51 | 131.95 | 79.41 | ||||||
| % of Revenue | 75.55 | 75.55 | 75.55 | 75.55 | 9.66 | 6.11 | 5.05 | 4.85 | |||||
| Gross Operating Profit | 40 | 40 | 40 | 40 | 0 | 0 | 0 | 0 | 0 | 5 | 40 | 113 | 211 |
| Change (%) | 0.00 | 0.00 | 0.00 | -100.00 | ∞ | 0.00 | 0.00 | 0.00 | 4,436.61 | 681.28 | 183.51 | 87.41 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 24.45 | 24.45 | 24.45 | 24.45 | 90.34 | 93.89 | 94.95 | 95.15 | |
| SG&A | 40 | 34 | 32 | 30 | 24 | 27 | 27 | 34 | 42 | 120 | 150 | 198 | 222 |
| Change (%) | -14.38 | -5.43 | -7.67 | -18.89 | 10.69 | 0.56 | 25.86 | 23.97 | 186.87 | 25.17 | 32.51 | 11.64 | |
| % of Revenue | 99.01 | 84.77 | 80.16 | 74.02 | 5,803.28 | 5,835.81 | 7,345.20 | 9,105.68 | 2,127.26 | 354.19 | 167.40 | 99.93 | |
| R&D | 60 | 64 | 69 | 61 | 51 | 40 | 34 | 24 | 19 | 37 | 41 | 49 | 43 |
| Change (%) | 6.60 | 7.56 | -10.43 | -16.44 | -22.77 | -15.20 | -30.08 | -18.90 | 92.74 | 11.50 | 19.22 | -11.45 | |
| % of Revenue | 149.57 | 159.44 | 171.49 | 153.60 | 8,656.99 | 7,341.27 | 5,133.19 | 4,162.88 | 653.41 | 96.91 | 41.21 | 19.51 | |
| OpEx | 99 | 98 | 101 | 91 | 75 | 67 | 61 | 57 | 61 | 157 | 193 | 253 | 276 |
| Change (%) | -1.76 | 3.05 | -9.55 | -17.24 | -11.65 | -8.83 | -5.27 | 6.29 | 156.77 | 23.18 | 31.02 | 8.79 | |
| % of Revenue | 248.59 | 244.21 | 251.65 | 227.62 | 14,535.81 | 13,252.62 | 12,553.93 | 13,344.10 | 2,790.33 | 457.22 | 213.66 | 124.29 | |
| Operating Income | -59 | -58 | -61 | -51 | -75 | -66 | -60 | -57 | -61 | -151 | -151 | -135 | -54 |
| Change (%) | -2.95 | 5.16 | -15.85 | 47.62 | -12.26 | -8.89 | -5.31 | 6.34 | 149.44 | -0.18 | -10.79 | -60.03 | |
| % of Revenue | -148.59 | -144.21 | -151.65 | -127.62 | -14,435.81 | -13,152.62 | -12,453.93 | -13,244.10 | -2,690.33 | -357.22 | -113.66 | -24.29 | |
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -1 | -1 | -1 | -2 | -14 | -24 | -32 | -37 |
| Change (%) | 17.24 | -0.00 | 1.76 | 8.67 | 38.56 | 40.12 | 88.90 | 20.67 | 732.21 | 70.00 | 36.57 | 15.75 | |
| % of Revenue | -0.72 | -0.85 | -0.85 | -0.86 | -113.76 | -159.39 | -301.09 | -363.32 | -246.23 | -55.68 | -27.12 | -16.79 | |
| Net Income | -57 | -56 | -59 | -55 | -82 | -69 | -61 | -52 | -51 | -154 | -173 | -164 | -81 |
| Change (%) | -2.74 | 6.38 | -7.28 | 48.71 | -15.72 | -11.78 | -14.78 | -1.86 | 203.27 | 12.81 | -5.46 | -50.48 | |
| % of Revenue | -142.83 | -138.92 | -147.79 | -137.03 | -15,000.22 | -13,232.97 | -11,276.86 | -11,067.25 | -2,733.34 | -410.18 | -138.31 | -36.62 | |
Source: Capital IQ
